Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Qyuns Therapeutics Co., Ltd. (02509) Stock Price History
Qyuns Therapeutics Co., Ltd. closed at HK$14.89 on Nov 12, 2026, −11.2% over 1 month, −21.6% over 1 year.
Price5-day MA25-day MAHang Seng IndexDisclosures
1-Month HighHK$16.76Oct 12
1-Month LowHK$14.33Nov 6
1-Week Change+0.6%vs Nov 5
1-Month Change−11.2%vs Oct 12
If you had invested HK$10,000 1 month ago, it would be worth HK$8,884 today (−11.2%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved +0.2%, while this stock moved −11.2%.
Last 10 Trading Days
Date
Close
Change
% Change
Nov 12 (Thu)
HK$14.89
+0.28
+1.92%
Nov 11 (Wed)
HK$14.61
−0.05
−0.34%
Nov 10 (Tue)
HK$14.66
+0.16
+1.10%
Nov 9 (Mon)
HK$14.50
+0.17
+1.19%
Nov 6 (Fri)
HK$14.33
−0.47
−3.18%
Nov 5 (Thu)
HK$14.80
−0.06
−0.40%
Nov 4 (Wed)
HK$14.86
−0.14
−0.93%
Nov 3 (Tue)
HK$15.00
−0.25
−1.64%
Nov 2 (Mon)
HK$15.25
−0.05
−0.33%
Oct 30 (Fri)
HK$15.30
+0.00
+0.00%
Price5-day MA25-day MAHang Seng IndexDisclosures
3-Month HighHK$17.97Aug 13
3-Month LowHK$14.33Nov 6
1-Month Change−11.2%vs Oct 12
3-Month Change−15.4%vs Aug 12
If you had invested HK$10,000 3 months ago, it would be worth HK$8,460 today (−15.4%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −4.4%, while this stock moved −15.4%.
Last 10 Trading Days
Date
Close
Change
% Change
Nov 12 (Thu)
HK$14.89
+0.28
+1.92%
Nov 11 (Wed)
HK$14.61
−0.05
−0.34%
Nov 10 (Tue)
HK$14.66
+0.16
+1.10%
Nov 9 (Mon)
HK$14.50
+0.17
+1.19%
Nov 6 (Fri)
HK$14.33
−0.47
−3.18%
Nov 5 (Thu)
HK$14.80
−0.06
−0.40%
Nov 4 (Wed)
HK$14.86
−0.14
−0.93%
Nov 3 (Tue)
HK$15.00
−0.25
−1.64%
Nov 2 (Mon)
HK$15.25
−0.05
−0.33%
Oct 30 (Fri)
HK$15.30
+0.00
+0.00%
Price25-day MA75-day MAHang Seng IndexDisclosures
6-Month HighHK$18.28May 12
6-Month LowHK$13.69Jun 26
3-Month Change−15.4%vs Aug 12
6-Month Change−18.5%vs May 12
If you had invested HK$10,000 6 months ago, it would be worth HK$8,146 today (−18.5%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −7.7%, while this stock moved −18.5%.
Monthly Closes
Month
Month-End Close
Monthly %
Nov 2026
HK$14.89
−2.7%
Oct 2026
HK$15.30
−9.7%
Sep 2026
HK$16.95
+1.7%
Aug 2026
HK$16.66
+2.2%
Jul 2026
HK$16.30
+15.0%
Jun 2026
HK$14.18
−15.9%
May 2026
HK$16.86
−2.0%
Price25-day MA75-day MAHang Seng IndexDisclosures
52-Week HighHK$23.30Jan 15
52-Week LowHK$13.69Jun 26
Year to Date−22.0%vs Dec 31
From 52-Week High−36.1%Jan 15
If you had invested HK$10,000 1 year ago, it would be worth HK$7,837 today (−21.6%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved −9.7%, while this stock moved −21.6%.
Monthly Closes
Month
Month-End Close
Monthly %
Nov 2026
HK$14.89
−2.7%
Oct 2026
HK$15.30
−9.7%
Sep 2026
HK$16.95
+1.7%
Aug 2026
HK$16.66
+2.2%
Jul 2026
HK$16.30
+15.0%
Jun 2026
HK$14.18
−15.9%
May 2026
HK$16.86
−2.0%
Apr 2026
HK$17.20
−9.9%
Mar 2026
HK$19.08
+12.4%
Feb 2026
HK$16.97
−18.6%
Jan 2026
HK$20.86
+9.2%
Dec 2025
HK$19.10
−15.2%
Nov 2025
HK$22.52
―
Price13-week MA26-week MAHang Seng Index
3-Year HighHK$33.88Sep 29, 2025
3-Year LowHK$6.70Feb 3, 2025
Annualized Return−12.1%
Max Drawdown−76.4%
If you had invested HK$10,000 3 years ago, it would be worth HK$7,107 today (−28.9%).Price change only; dividends and fees are not included.
Over the same period the Hang Seng Index moved +47.4%, while this stock moved −28.9%.
Yearly Closes
Year
Year-End Close
Yearly %
2026 (YTD)
HK$14.89
−22.0%
2025
HK$19.10
―
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Mar 2024). Please check the latest prices before trading.
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No.7Disclosure2026/11/05 21:10
事業の状況
VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICS FOR A PRECLINICAL BISPECIFIC ANTIBODY PROGRAM TARGETING TL1A AND IL-17
事業の状況
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL STUDY RESULTS OF OTURKIBART (QX005N) FOR TREATMENT OF PRURIGO NODULARIS PRESENTED AS A LATE-BREAKING ORAL PRESENTATION AT EADV 2026
継続的な関連当事者取引／取締役・重要な執行役員の異動／取締役の選任（総会付議）
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE REVISION OF ANNUAL CAPS FOR THE QX001S FRAMEWORK AGREEMENT; AND RESIGNATION AND PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR